Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Iversen

Showing results (51-60 of 156) with videos related to

Pageof 16
Sort By:
BJU International|September 24, 2013
Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancerFrederik Birkebaek Thomsen, Ib Jarle Christensen, Klaus Brasso, et al.
European Journal of Hybrid Imaging|August 24, 2022
Early acquisition of [<sup>18</sup>F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better!Mette Louise Gram Kjærulff, André H Dias, Peter Iversen, et al.
Danish Medical Journal|December 24, 2016
Antibiotic prophylaxis and complications following prostate biopsies - a systematic reviewNina Klemann, John Thomas Helgstrand, Klaus Brasso, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|January 24, 2009
C-type natriuretic peptide in prostate cancerSoeren Junge Nielsen, Peter Iversen, Jens F Rehfeld, et al.
Scandinavian Journal of Urology|November 22, 2013
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetateFrederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, et al.
Acta Neuropsychiatrica|April 24, 2015
α2-adrenoceptor binding in Flinders-sensitive line compared with Flinders-resistant line and Sprague-Dawley ratsThea Pinholt Lillethorup, Peter Iversen, Gregers Wegener, et al.
EJNMMI Physics|November 13, 2021
Practical kidney dosimetry in peptide receptor radionuclide therapy using [<sup>177</sup>Lu]Lu-DOTATOC and [<sup>177</sup>Lu]Lu-DOTATATE with focus on uncertainty estimatesPeter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, et al.
BJU International|August 20, 2011
Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancerMartin Andreas Røder, Ib Jarle Christensen, Kasper D Berg, et al.
EJNMMI Research|December 19, 2023
[<sup>18</sup>F]FDOPA PET/CT is superior to [<sup>68</sup>Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytomaPeter Iversen, Stine Kramer, Andreas Ebbehoj, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|April 16, 2011
Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluationKasper Drimer Berg, Birgitte Grønkaer Toft, Martin Andreas Røder, et al.
Pageof 16

Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
BJU International|September 24, 2013
Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancerFrederik Birkebaek Thomsen, Ib Jarle Christensen, Klaus Brasso, et al.
European Journal of Hybrid Imaging|August 24, 2022
Early acquisition of [<sup>18</sup>F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better!Mette Louise Gram Kjærulff, André H Dias, Peter Iversen, et al.
Danish Medical Journal|December 24, 2016
Antibiotic prophylaxis and complications following prostate biopsies - a systematic reviewNina Klemann, John Thomas Helgstrand, Klaus Brasso, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|January 24, 2009
C-type natriuretic peptide in prostate cancerSoeren Junge Nielsen, Peter Iversen, Jens F Rehfeld, et al.
Scandinavian Journal of Urology|November 22, 2013
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetateFrederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, et al.
Acta Neuropsychiatrica|April 24, 2015
α2-adrenoceptor binding in Flinders-sensitive line compared with Flinders-resistant line and Sprague-Dawley ratsThea Pinholt Lillethorup, Peter Iversen, Gregers Wegener, et al.
EJNMMI Physics|November 13, 2021
Practical kidney dosimetry in peptide receptor radionuclide therapy using [<sup>177</sup>Lu]Lu-DOTATOC and [<sup>177</sup>Lu]Lu-DOTATATE with focus on uncertainty estimatesPeter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, et al.
BJU International|August 20, 2011
Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancerMartin Andreas Røder, Ib Jarle Christensen, Kasper D Berg, et al.
EJNMMI Research|December 19, 2023
[<sup>18</sup>F]FDOPA PET/CT is superior to [<sup>68</sup>Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytomaPeter Iversen, Stine Kramer, Andreas Ebbehoj, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|April 16, 2011
Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluationKasper Drimer Berg, Birgitte Grønkaer Toft, Martin Andreas Røder, et al.
Pageof 16